DelveInsight’s “Acute on Chronic Liver Failure Market Insight, Epidemiology and Market Forecast 2032” report provides current treatment practices, emerging drugs, Acute On Chronic Liver Failure market share of the individual therapies, current and forecasted Acute On Chronic Liver Failure market size from 2019 to 2032 segmented by seven major markets. The report also offers current Acute On Chronic Liver Failure therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute On Chronic Liver Failure market.
Acute On Chronic Liver Failure Overview
The term ‘acute-on-chronic liver failure’ (ACLF) defines an abrupt and life-threatening worsening of clinical conditions in patients with cirrhosis or chronic liver disease. ACLF is a serious condition with very high morbidity and mortality. According to European Association for the Study of the Liver – Chronic Liver Failure (EASL-CLIF) Consortium the definition of ACLF is based on the existence of the failure of 1 of the 6 major organ systems. The failure of each organ system is assessed using the CLIF-C Organ Failure scale
According to NACSELD, the most prevalent organ system failures were brain (36%), followed by circulatory (16%), kidney (13%), and respiratory (9%).3 The observed 30-day mortality rate progressively increased from 4% in patients without any OF, to 27%, 49%, 64% and 77% in patients with 1, 2, 3, or 4 OFs, respectively.
The most frequent precipitating disorders for acutely decompensated cirrhosis, with or without ACLF, were both hepatic (alcohol-induced liver injury) and extrahepatic (bacterial infections or gastrointestinal haemorrhage).
Acute On Chronic Liver Failure Epidemiological Insights
According to Delveinsight, grade 1 cases accounted for maximum number of acute on chronic liver failure cases.
Acute On Chronic Liver Failure Treatment Market
At present, there is no specific treatment accessible for patients with ACLF. The management of ACLF includes etiology-based treatment, controlling and treating complications, providing artificial liver support system, and liver transplantation. Admission of patients with ACLF should be considered preferably in transplant centers. Organ functions need to be monitored closely and organ-specific treatment is required to restrict the development of multiorgan failures.
The main principles of management in these patients are to provide support to each of the organs with failure and to promote recovery of the hepatic gland. The current treatment includes the use of devices for detoxification, antiviral therapy, and liver transplantation.
Promising Therapiesin the Acute On Chronic Liver Failure Pipeline
Discover more about Acute On Chronic Liver Failure therapies in the pipeline @ Acute On Chronic Liver Failure Drugs
Leading Companies Working in the Acute On Chronic Liver Failure Market
To understand key companies related to the Acute On Chronic Liver Failure Market, get a snapshot of the Acute On Chronic Liver Failure Regulatory and Patent Analysis.
Scope of the Acute On Chronic Liver Failure Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Acute On Chronic Liver Failure Pipeline Therapies: PE-A (Albutein-5%), VS-01, HepaStem, and others
Key Acute On Chronic Liver Failure Companies: Grifols Therapeutics, Versantis AG, Promethera Biosciences, and others
Therapeutic Assessment: Acute On Chronic Liver Failure current marketed and emerging therapies
Acute On Chronic Liver Failure Market Dynamics: Acute On Chronic Liver Failure market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Acute On Chronic Liver Failure Market Access and Reimbursement
Table of Contents
1. Acute On Chronic Liver Failure Market Key Insights
2. Acute On Chronic Liver Failure Market Report Introduction
3. Acute On Chronic Liver Failure Market Overview at a Glance
4. Acute On Chronic Liver Failure Market Executive Summary
5. Disease Background and Overview
6. Acute On Chronic Liver Failure Treatment and Management
7. Acute On Chronic Liver Failure Epidemiology and Patient Population
8. Patient Journey
9. Acute On Chronic Liver Failure Emerging Drugs
10. 7MM Acute On Chronic Liver Failure Market Analysis
11. Acute On Chronic Liver Failure Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Acute On Chronic Liver Failure Market Drivers
15. Acute On Chronic Liver Failure Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Report Offerings by DelveInsight:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Kritika Rehani
[email protected]
+1(919)321-6187
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
